 The study compares the cost effectiveness of four influenza vaccines and non-vaccination in Italian elderly population, finding MF59-TIV to be the most cost-effective option with an ICER of €10,750 per QALY. This article was authored by Stefano Capri, Marco Barbieri, Chiara D'Avoire, and others.